| total fat |
phenotype |
2 |
1 |
TF |
| total power |
phenotype |
4 |
3 |
|
| total RNA |
drug |
6 |
1 |
RNA, total RNAs |
| total variance |
phenotype |
2 |
1 |
σ2P |
| Tourette’s syndrome |
phenotype |
6 |
4 |
Tourette syndrome |
| Tourette syndrome |
phenotype |
19 |
1 |
Gilles de la Tourette syndrome, TD, TS, Tourette, Tourette cases, Tourette diagnosis, Tourette’s syndrome, tics |
| toxic effects |
phenotype |
2 |
1 |
|
| TP53 |
gene |
33 |
12 |
P53, TP53, Trp53, p53, p53 knockdown, p53KD, tumor protein p53 |
| TPH1 |
gene |
3 |
2 |
tryptophan hydroxylase 1 |
| TPH2 |
gene |
4 |
3 |
tryptophan hydroxylase 2 |
| TRA-1-60 |
phenotype |
5 |
2 |
|
| TRA-1-81 |
phenotype |
2 |
1 |
|
| trace fear conditioning |
phenotype |
2 |
1 |
trace (hippocampal-dependent) fear conditioning |
| TRAF3 |
gene |
2 |
2 |
|
| Trail |
drug |
2 |
2 |
TNF-related apoptosis-inducing ligand, TNFSF10 |
| training set |
cohort |
5 |
1 |
training sample |
| trait |
phenotype |
46 |
29 |
biomedical trait, disease trait, multiple traits, phenotype, quantitative trait, quantitative trait results, quantitative traits, trait, trait analyzed in GWAS i, trait being studied, trait data, trait-associated variant, traits, unique traits, yi* |
| trait anxiety |
phenotype |
6 |
4 |
anxiety, high trait anxiety, trait anxiety |
| trait-associated variant |
cohort |
5 |
3 |
10,317 variants, GWAS SNPs, GWAS variant, trait-associated variant |
| tranquilizers |
drug |
3 |
— |
|
